Clinical Trial open to United Rheumatology Members

Beginning in June, Scipher Medicine will begin enrolling UR member sites for a trial called  NETWORK-004: A Prospective Observational Trial to Validate the Ability of PrismRA to Predict Non-Responders to anti-TNF Therapies. The primary endpoint of this study is the predictive ability of the PrismRA response classifier to identify anti-TNF therapy non-responders in female and/or all rheumatoid arthritis patients with moderate or high disease activity, using standard clinical outcome measures (CDAI, ACR50,DAS-28). The trial will serve as a lead-in to a prospective, randomized, interventional trial (NETWORK-001) Scipher will aim to kick off by year-end.

Learn More About How United Rheumatology Can Support You

Join Max Hamburger, M.D., Founder and Executive Chairman,United Rheumatology and the Clinical Operations team from Scipher Medicine for a 45-minute webinar. Participants will learn more about the clinical trial, enrollment, patient identification and selection process. Members can register via the link located in the sidebar.